Effect of high-dose thymidine infusions in patients with mycosis fungoides
โ Scribed by D. W. Kufe; M. M. Wick; S. Moschella; P. Major
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 381 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
The antitumor effect of thymidine has been demonstrated in patients with leukemia and lymphoma. This report summarizes the treatment of three patients with mycosis fungoides, a chronic T-cell lymphoma. Four cour.ses of thymidine (75 glm'lday) were administered by continuous infusion for 4-7 days. Steadystate serum thymidine levels were in the range of 1-3 m ~. Associated toxicities were minimal and consisted of mild headache and anorexia. Myelosuppression was manifested by transient declines in the peripheral leukocyte count. One patient had extensive clearing of diffuse erythematous plaques on the trunk and extremities that persisted for over one month. A second patient had partial clearing of plaques that persisted for two weeks following therapy and a third patient had a minimal response with 25% reduction in lymphadenopathy and noduloulcerative lesions. These responses indicate the effectiveness of thymidine as a single agent in the treatment of mycosis fungoides.
๐ SIMILAR VOLUMES
Mycosis fungoides is the most common cutaneous lymphoma in the US, and it is increasing rapidly in both incidence and mortality. Our knowledge of its prognosis derives primarily from case series, which are subject to possible selection bias and other limitations. The current analysis examines trends
BACKGROUND. An earlier trial of raloxifene, conducted in women with metastatic breast carcinoma who initially had responded to tamoxifen and subsequently developed disease progression, suggested no antitumor activity for raloxifene in tamoxifen-refractory disease. However, preclinical studies and pr
The authors sought to evaluate trends in survival among a population-based group of patients with mycosis fungoides, in response to informal evidence of improved prognosis and concerns about the influence of detection bias on incidence data. METHODS. Data used in this study were drawn from the Surve
W einstock and Reynes 1 present intriguing data from the Surveil- lance, Epidemiology and End Results (SEER) program about the prognosis of patients in the United States with newly diagnosed mycosis fungoides (MF). They report improved overall and relative survival over a registration period of 20 y